CAN
Life Sciences
Innovation, patient access and pricing are driving the transformation of the life sciences
This is a time of enormous disruption in the life sciences. New IP being generated and new entrants from the technology industry are accelerating the dawn of personalized medicine.
With a nearly constant stream of capital and emerging technologies, biotech start-ups have proliferated; investors and Big Pharma are chasing innovations; and drug approvals have hit record levels globally.
Talent acquisition has become a key indicator of future success, with well-funded early stage companies and global pharma companies competing on an increasingly level playing field.
Canada
In the US, strong financial performance has fostered countless innovations and fueled M&A activity across the sector as MNCs look to optimize their businesses.
But drug pricing continues to steal the headlines in North America. As specialty pharma consolidators scramble to find a new business model, there has been an explosion in clinical programs and drug launches as innovators look to unmet needs to secure revenue.
Odgers Berndtson’s global Life Sciences Practice supports biotechnology and pharmaceutical companies across the world in developing board and executive teams with the skills and experience to deliver their key business objectives.
People
Insights
The age of Precision Medicine
John Jakenfelds looks at the disruptive forces at work in the life sciences arena and the extraor...
Laying down a biomarker
What are the challenges that researchers face in developing personalised medicine – treatment tha...
What next for Medtech?
As the healthcare sector shifts in response to new economic and social trends, recruitment needs...
